Articles

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

Centre for Haematology, Department of Medicine, Imperial College, London, UK
Centre for Haematology, Department of Medicine, Imperial College, London, UK
Centre for Haematology, Department of Medicine, Imperial College, London, UK;Imperial College Healthcare NHS Trust, London, UK
Centre for Haematology, Department of Medicine, Imperial College, London, UK;Sarah Cannon Molecular Diagnostics, HCA Healthcare UK, London, UK
Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College, London, UK
Centre for Haematology, Department of Medicine, Imperial College, London, UK
Centre for Haematology, Department of Medicine, Imperial College, London, UK;Imperial College Healthcare NHS Trust, London, UK
Imperial College Healthcare NHS Trust, London, UK
Centre for Haematology, Department of Medicine, Imperial College, London, UK;Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK
Centre for Haematology, Department of Medicine, Imperial College, London, UK;Imperial College Healthcare NHS Trust, London, UK
Centre for Haematology, Department of Medicine, Imperial College, London, UK;Imperial College Healthcare NHS Trust, London, UK
Centre for Haematology, Department of Medicine, Imperial College, London, UK;Imperial College Healthcare NHS Trust, London, UK
Centre for Haematology, Department of Medicine, Imperial College, London, UK;Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore MD, USA
Centre for Haematology, Department of Medicine, Imperial College, London, UK
Centre for Haematology, Department of Medicine, Imperial College, London, UK
Centre for Haematology, Department of Medicine, Imperial College, London, UK;Imperial College Healthcare NHS Trust, London, UK
Vol. 104 No. 12 (2019): December, 2019 https://doi.org/10.3324/haematol.2018.200220